en POLSKI
eISSN: 2083-8441
ISSN: 2081-237X
Pediatric Endocrinology Diabetes and Metabolism
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
4/2022
vol. 28
 
Share:
Share:
more
 
 
abstract:
Editorial

Lipid disorders in children – an underestimated problem

Małgorzata Wójcik
1

1.
Department of Pediatric and Adolescent Endocrinology, Chair of Pediatrics, Pediatric Institute, Jagiello-nian University Medical College, Krakow, Poland
Pediatr Endocrinol Diabetes Metab 2022; 28 (4): 241–244
Online publish date: 2022/12/23
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
PlumX metrics:
Lipid metabolism disorders (dyslipidemias) are a heterogenic group of diseases that may occur at any age, and may be tran-sient or last throughout life. They are one of the most common pathologies in the pediatric population. In the United States, ap-proximately 20% of children (age 6 to 19 years) have abnormal levels of at least one lipid parameter value [1]. A similar frequen-cy was found in the German population [2]. In adults, dyslipidemia is an established risk factor for cardiovascular disease (CVD). Because dyslipidemia often begins in childhood and adolescence, identifying children with dyslipidemia and successfully im-proving their lipid profile may reduce their risk of accelerated atherosclerosis and premature CVD [3]. Scientific evidence con-firmed the relationship between hyperlipidemia at an early age and unfavorable changes in morphology of arterial intima layer which support the hypothesis that atherosclerosis has an early onset, being a chronic and progressive process [4, 5]. There are many factors affecting lipid metabolism, including genetic background, external factors, and a combination of these. The basic classification is based on the causes of the disorders and distinguishes the following: 1. primary dyslipidemias, that are a heterogeneous group of diseases of mono, or polygenic etiology, and 2. secondary dyslipidemias resulting from the association of risk factors with external factors or other pathologies [6]. Subdivision can also be according to biochemical changes as hyper-cholesterolemia (increased total cholesterol – TC and low-density lipoprotein cholesterol [LDL-C] levels), hypertriglyceridemia (elevated triglycerides – TG), low isolated levels of high-density lipoprotein [HDL-C] cholesterol, and lastly, simultaneously in-creased TC and TG associated with low levels of HDL-C (mixed or combined) [7]. Dyslipidemia often appears as a synonym for hyperlipidemia however, hypolipidemias such as abetalipoproteinemia, familial hypobetalipoproteinemia, or sterol synthesis defects should also be considered [6]. There are 25 forms of monogenic lipid disorders described in the literature [8]. The most common monogenic conditions include familial hypercholesterolemia (FH) caused by hepatic LDL-receptor dysfunction (ap-proximately 85–90% of patients), changes in the apolipoprotein B protein receptor on the low-density lipoprotein particle sur-faces (apolipoprotein B deficit), or a gain in the proprotein convertase subtilisin/kexin type...


View full text...
keywords:

dyslipidemia, familial hypercholesterolemia, statins, hypertriglycerydemia, children


Quick links
© 2023 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.